Month: June 2025

Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m. ET BOSTON, June 01, 2025 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today presented updated data from the company’s Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Ficerafusp alfa is a first-in-class...

Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCCA Single Dose of ALLO-316 Achieved a 31% Confirmed Response Rate Four of Five Confirmed Responders Remain in Response Including One Ongoing Remission Over 12 MonthsRobust Expansion, Persistence, and Tumor Infiltration of ALLO-316 Seen with Standard Lymphodepletion, Showcasing Dagger® Technology as a Next-Generation Allogeneic Platform Phase 1 Safety Profile was Manageable; Proactive Diagnostic and Management Strategies Proved Effective in Mitigating IEC-HS While Preserving EfficacySOUTH SAN FRANCISCO, Calif., June 01, 2025 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology...

– RP1 plus nivolumab generated robust responses in both injected and non-injected lesions – – Deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only and were generally well tolerated – WOBURN, Mass., June 01, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented two posters highlighting data updates for RP1 (vusolimogene oderparepvec) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago. “The new analyses we presented from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma confirms our belief in the systemic...

33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year post-treatment analysis1Tolerability remained consistent, with fewer treatment discontinuations due to adverse events among pre-menopausal patients1Rising breast cancer diagnosis rates and more aggressive disease in younger women underscore importance of early detection and care with effective and tolerable treatments that help prevent cancer recurrence2Separate real-world analysis presented at ASCO demonstrates differences in treatment outcomes that underscore critical need to improve care for Black patients with EBC3Basel, June 1, 2025 – Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety of Kisqali® (ribociclib) plus...

First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer’s new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible  REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, and Korea University, a leading research institution committed to innovation and global impact, today announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer’s newly launched Proteograph® ONE Assay and SP200 Automation Instrument along with the Thermo Scientific™ Orbitrap™...

23,231 vehicles were delivered in May 2025, increasing by 13.1% year-over-year 89,225 vehicles were delivered year-to-date in 2025, increasing by 34.7% year-over-year Cumulative deliveries reached 760,789 as of May 31, 2025SHANGHAI, June 01, 2025 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its May 2025 delivery results. The Company delivered 23,231 vehicles in May 2025, representing an increase of 13.1% year-over-year. The deliveries consisted of 13,270 vehicles from the Company’s premium smart electric vehicle brand NIO, 6,281 vehicles from the Company’s family-oriented smart electric vehicle brand ONVO, and 3,680 vehicles from the Company’s small smart high-end electric car brand FIREFLY....

Delivers 33,525 units in May, up 230% YoY 30,000+ vehicles delivered monthly for seventh consecutive monthGUANGZHOU, China, June 01, 2025 (GLOBE NEWSWIRE) — XPeng Inc. (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced its vehicle delivery results for May 2025. In May 2025, XPENG delivered 33,525 Smart EVs, representing growth of 230% year-over-year, surpassing 30,000 units for the seventh consecutive month. For the first five months of 2025, XPENG delivered 162,578 Smart EVs, marking a 293% increase compared to the same period last year. On May 28th, the Company launched the MONA M03 Max. MONA M03 Max lowers the entry barrier for urban AI smart driving to the 150,000 RMB range for the first time, making advanced vehicle technology more accessible...

BEIJING, China, June 01, 2025 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered 40,856 vehicles in May 2025, representing a year-over-year increase of 16.7%. As of May 31, 2025, Li Auto’s cumulative deliveries reached 1,301,531. Li Auto has completed a comprehensive upgrade of its entire model lineup to new versions over the past month. The deliveries of Li MEGA Home began in late May, and its production ramp up is accelerating as orders significantly exceeded expectations. The new Li L series demonstrates substantially enhanced product strengths, with each upgrade tailored to genuine user needs and optimized for high-frequency usage scenarios. Li L9 features the dual-chamber air suspension and dual-valve CDC flagship...